125 completed, 37 unknown, 33 terminated, 31 recruiting. 260 Phase 2, 63 Phase 1, 32 Phase 3.
Follow Cranial Nerve Diseases: new trials by email Literature Review of Cranial Nerve Diseases trials Research Report on Cranial Nerve Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle | Phase 2 | Withdrawn | Michael, Levy M.D.,Ph.D. | 2026-12-31 | 2025-07-16 | |
| Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder Anti-BAFFR CART - Neuromyelitis Optica Spectrum Disorder | Phase 1 / Phase 2 | Not yet recruiting | Tianjin Medical University General Hospital | 20 | 2026-12-01 | 2026-10-16 |
| Selumetinib for NF2-Related Schwannomatosis Selumetinib - Neurofibromatosis Type 2, NF2 | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 20 | 2026-12-01 | 2026-10-28 |
| Natural History of MTBI-related Convergence Insufficiency & Effectiveness of Vision Therapy for MTBI-related CI Office-Based Vergence/Accommodative Therapy with Movement (OBVAM) - Convergence Insufficiency | Phase 2 | Not yet recruiting | Salus University | 100 | 2026-11-01 | 2025-02-27 |
| A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease CTX112 - Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica | Phase 1 / Phase 2 | Not yet recruiting | CRISPR Therapeutics | 220 | 2026-11-01 | 2026-10-22 |
| A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies NIO752, Placebo - Progressive Supranuclear Palsy, Corticobasal Degeneration | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 48 | 2026-10-23 | 2026-10-09 |
| A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage ASP2767, Sham ASP2767, Prophylactic Regimen A - Glaucoma | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 156 | 2026-10-07 | 2026-10-22 |
| Pain After Strabismus Surgery Tylenol - Strabismus | Phase 2 | Suspended | Ann & Robert H Lurie Children's Hospital of Chicago | 80 | 2026-10-01 | 2026-07-30 |
| Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy | Phase 1 / Phase 2 | Recruiting | Prabesh Kanel | 15 | 2026-10-01 | 2026-11-05 |
| A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma Zanzalintinib - Metastatic Olfactory Neuroblastoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 16 | 2026-10-01 | 2026-11-10 |
| RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia RP-008, Varenicline tartrate - Trigeminal Neuralgia | Phase 1 / Phase 2 | Recruiting | Kriya Therapeutics, Inc. | 24 | 2026-09-10 | 2026-10-23 |
| Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder Placebo, IL-2 (interleukin 2) - Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 60 | 2026-08-30 | 2026-09-09 |
| Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy Teprotumumab N01, Intravenous Methylprednisolone (IVMP) - Thyroid Eye Disease, TED, Graves Ophthalmopathy | Phase 2 | Not yet recruiting | Sun Yat-sen University | 60 | 2026-08-01 | 2026-05-19 |
| Luvometinib in Combination With Serplulimab for NF2-Related Tumors Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2 | Phase 1 / Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 30 | 2026-07-31 | 2026-07-16 |
| The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1 AADvac1, Matching Placebo - PSP - Progressive Supranuclear Palsy | Phase 2 | Enrolling by invitation | Adam Boxer | 146 | 2026-07-29 | 2026-11-05 |
| The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31 LM11A-31, Matching Placebo - PSP - Progressive Supranuclear Palsy | Phase 2 | Enrolling by invitation | Adam Boxer | 147 | 2026-07-29 | 2026-11-05 |
| The Progressive Supranuclear Palsy Clinical Trial Platform AADvac1, LM11A-31 - Progressive Supranuclear Palsy(PSP) | Phase 2 | Recruiting | Adam Boxer | 440 | 2026-07-29 | 2026-11-10 |
| Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 200 | 2026-07-18 | 2026-07-20 |
| Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II Trineumin - Neurofibromatosis Type II, NF2 | Phase 1 / Phase 2 | Not yet recruiting | PRG Science & Technology Co., Ltd. | 25 | 2026-07-01 | 2026-01-23 |
| A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy G01 Eye Drops 100μg/ml, G01 Eye Drops 200μg/ml, Placebo of G01 Eye Drops - Primary Open-Angle Glaucoma, Optic Nerve Injury | Phase 2 | Recruiting | Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. | 90 | 2026-03-18 | 2026-08-24 |
Showing 20 of 260. Sign in to see all of them.
Neuromyelitis Optica (39) · Supranuclear Palsy, Progressive (31) · Neurofibromatosis 2 (24) · Esthesioneuroblastoma, Olfactory (22) · Neuroma, Acoustic (22) · Optic Neuritis (22) · Astrocytoma (21) · Optic Nerve Glioma (21) · Trigeminal Neuralgia (21) · Brain Neoplasms (16) · Central Nervous System Neoplasms (16) · Oligodendroglioma (16) · Multiple Sclerosis (15) · Optic Atrophy, Hereditary, Leber (15) · Meningioma (14)
Nervous System Diseases (258) · Eye Diseases (167) · Optic Nerve Diseases (118) · Neurodegenerative Diseases (83) · Pathological Conditions, Signs and Symptoms (81) · Neoplasms (80) · Neoplasms by Histologic Type (76) · Neoplasms, Nerve Tissue (75) · Neuroectodermal Tumors (75) · Neoplasms by Site (73) · Neoplasms, Germ Cell and Embryonal (73) · Central Nervous System Diseases (72) · Brain Diseases (66) · Neurologic Manifestations (66)
Bevacizumab (7) · Carboplatin (7) · Filgrastim (6) · Methylprednisolone (6) · Radiotherapy (6) · Rituximab (6) · Etoposide (5) · Prednisone (5) · AZD 6244 (4) · Cisplatin (4) · Methylprednisolone Acetate (4) · Methylprednisolone Hemisuccinate (4) · Peripheral Blood Stem Cell Transplantation (4) · Saline Solution (4) · eculizumab (4)
National Cancer Institute (NCI) (13) · Tianjin Medical University General Hospital (10) · Beijing Tiantan Hospital (4) · Memorial Sloan Kettering Cancer Center (4) · Adam Boxer (3) · Amgen (3) · Biogen (3) · Duke University (3) · Isfahan University of Medical Sciences (3) · M.D. Anderson Cancer Center (3) · Massachusetts General Hospital (3) · NYU Langone Health (3) · Northwestern University (3) · Novartis Pharmaceuticals (3) · University of Calgary (3)
United States (131) · China (33) · Canada (32) · United Kingdom (24) · France (22) · Germany (20) · Spain (18) · Australia (15) · Italy (15) · Japan (7) · New Zealand (7) · Iran (6) · Poland (6) · South Korea (6) · Switzerland (6)
Adam Boxer, MD, PhD (3) · Anne-Marie Wills, MD (3) · Fu-Dong Shi, MD,PhD (3) · Henry S. Friedman, MD (3) · Irene Litvan, MD (3) · Julio Rojas-Martinez, MD, PhD (3) · Matthias A Karajannis, MD, MS (3) · Michael Levy, MD, PhD (3) · Charalampos Floudas, M.D. (2) · Christian Debry, MD (2) · D. Bradley Welling, MD, PhD (2) · Erling A Tronvik, PhD, MD (2)
PMID 38825840, PMID 1463007, PMID 16408203, PMID 1674640, PMID 16899778, PMID 17545536, PMID 17610262, PMID 18441370, PMID 18441371, PMID 18774912, PMID 18989154, PMID 1928099, PMID 19694164, PMID 19838774, PMID 20126486, PMID 20381270, PMID 20606544, PMID 21211990, PMID 21343523, PMID 21444653, PMID 21621166, PMID 21788663, PMID 21791630, PMID 22236384, PMID 22294344, PMID 22612072, PMID 22644094, PMID 22742888, PMID 22926853, PMID 23063736, PMID 23131255, PMID 23263355, PMID 23623397, PMID 23764350, PMID 24287594, PMID 24396955, PMID 24438512, PMID 24756302, PMID 24756514, PMID 24781936, PMID 24873720, PMID 25223501, PMID 25370510, PMID 25370513, PMID 25408174, PMID 25950380, PMID 25965900, PMID 26024112, PMID 26062933, PMID 26083135
U10CA098543 (5), 2017 (3), R01AG085029 (3), 2016 (2), 2018 (2), 2019 (2), 2023 (2), 1IK2RX001180-01A2 (1), 2008 (1), 2014 (1), 2015 (1), K23NS050485 (1), N01CM62202 (1), P30CA006516 (1), P30CA006927 (1)